Teva Pharma's most recent trend suggests a bearish bias. One trading opportunity on Teva Pharma is a Bear Call Spread using a strike $46.00 short call and a strike $51.00 long call offers a potential 7.3% return on risk over the next 11 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $46.00 by expiration. The full premium credit of $0.34 would be kept by the premium seller. The risk of $4.66 would be incurred if the stock rose above the $51.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Teva Pharma is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Teva Pharma is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Teva Pharma
Don't Blame Mylan's CEO for EpiPen's Soaring Price, Blame the U.S. Healthcare System
Sun, 09 Oct 2016 18:28:54 GMT
Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion, Team Up To Market mAb Biosimilars
Fri, 07 Oct 2016 18:11:50 GMT
3 Value Stocks Near 52-Week Lows Worth Buying
Thu, 06 Oct 2016 14:59:06 GMT
Teva to Divest Actavis Generics' UK & Ireland Operations
Thu, 06 Oct 2016 13:16:01 GMT
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Thu, 06 Oct 2016 12:00:00 GMT
Business Wire – JERUSALEM and INCHEON, South Korea–(BUSINESSWIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA), Celltrion, Inc. and Celltrion Healthcare today announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan® (rituximab), which is used to treat patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Wegener’s Granulomatosis and Microscopic Polyangiitis (MPA). “This commercial partnership with Celltrion enables Teva to expand into the upcoming wave of biosimilars and build on its strong position in the biosimilar space,” said Siggi Olafsson, President & CEO of Global Generic Medicines, Teva Pharmaceuticals.
Also on Market Tamer…
Follow Us on Facebook